SUBSCRIBE
SUBSCRIBE
News   Policy

UK’s NICE Rejects GlaxoSmithKline, Genmab A/S Leukemia Drug, Arzerra

June 24, 2010 | 
1 min read

Reuters -- GlaxoSmithKline leukemia drug Arzerra, licensed from Denmark’s Genmab, has been rejected by Britain’s cost watchdog NICE in preliminary draft guidance.

Regulatory
GlaxoSmithKline
MORE ON THIS TOPIC
Pictured: Facade of Moderna's building in Massachusetts
RSV
Moderna’s RSV Vaccines Run Into Safety Roadblock
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More
December 9, 2024
 · 
7 min read
 · 
Tristan Manalac